TY - JOUR T1 - Impact of symptoms of anxiety and depression on COPD Assessment Test scores JF - European Respiratory Journal JO - Eur Respir J SP - 898 LP - 900 DO - 10.1183/09031936.00163913 VL - 43 IS - 3 AU - Christina W. Hilmarsen AU - Sarah Wilke AU - Harald Engan AU - Martijn A. Spruit AU - Johan Rodenburg AU - Daisy J.A. Janssen AU - Sigurd Steinshamn AU - Paul W. Jones AU - Emiel F.M. Wouters AU - Line Oldervoll AU - Frits M.E. Franssen Y1 - 2014/03/01 UR - http://erj.ersjournals.com/content/43/3/898.abstract N2 - Anxiety and depression are common comorbidities in patients with chronic obstructive pulmonary disease (COPD) and affect patients’ health status [1, 2]. Health status in COPD patients is frequently assessed by the St George’s Respiratory Questionnaire (SGRQ), which is a validated disease-specific questionnaire widely used in clinical trials [3], but complex and time-consuming to complete and score. Consequently, the COPD Assessment Test (CAT) has been developed [4]. This is a disease-specific health status questionnaire containing eight items with good sensitivity, reliability and responsiveness [4]. CAT scores are strongly positively correlated with SGRQ scores in patients with COPD [4]. Therefore, it is reasonable to hypothesise that those COPD patients with symptoms of anxiety and/or depression will report higher CAT scores (equalling worse health status) compared to those without symptoms.The latest version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) document [5] recommends the CAT as a tool to assess the impact of COPD on the individual patient beyond airflow limitation. Although it was known that clinically relevant symptoms of anxiety and depression are more common in patients in GOLD stage IV compared to patients in GOLD stages I and II [1], the frequency distribution of patients with symptoms of anxiety and depression across the updated GOLD classification remains unknown. Recently, Sillen et al. [6] reported a prevalence of symptoms of anxiety and depression of 38% and 32%, respectively, in COPD patients with GOLD group D.We aimed to assess … ER -